Thank you for contacting us! We will be in touch soon! In the meantime, feel free to continue browsing our site.
Events
- Webinar: Inflammatory Disease Modeling for Preclinical Studies | January 24, 2023
- PepTalk 2023 | January 05, 2023
- 7th Tumor Models for Immuno-Oncology Summit | December 27, 2022
- Biocytogen BDL Team to Participate in the 41st Annual JPM Healthcare Conference, the Biotech Showcase and BIO Partnering at JPM | December 21, 2022
- American Society for Cell Biology 2022 | November 29, 2022
- Antibody Engineering & Therapeutics 2022 | November 22, 2022
News
- Biocytogen and Hansoh Pharma Announce an Antibody License Agreement | January 03, 2023
- Biocytogen Launches RenNano® Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery | December 30, 2022
- Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008 | December 19, 2022
- Biocytogen Enters into Antibody Agreement with ADC Therapeutics | November 28, 2022
- First Patient Dosed in Phase 1/2 Trial Evaluating YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Patients | November 21, 2022
- Selecting the Right Platform for Your Antibody Discovery Project | November 17, 2022
